Companies Dominating the Pancreatic Cancer Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG Pfizer Inc.
- Aduro Biotech Inc.
- Clovis Oncology Inc.
- NewLink Genetics Corp
- Infinity Pharmaceuticals, Inc.
- Celgene Corporation
- Novocure
- AIM ImmunoTech Inc.
The market is propagating with the continuous R&D activity and cohort, led by key players. They are investing heavily in developing new treatment alternatives with higher response rates and survival possibilities. For instance, in December 2024, NANOBIOTIX shared updates from the phase I trial on radiotherapy-activated NBTXR3 (JNJ-1900), treating patients with locally advanced pancreatic cancer or borderline resectable pancreatic cancer. They revealed the completion of the dose escalation and dose expansion parts of this evaluation process, conducted by The University of Texas MD Anderson Cancer Center. These research initiatives further inspire more companies to participate in this field. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of pancreatic cancer is evaluated at USD 2.72 billion.
The global pancreatic cancer market is set to rise from USD 2.48 billion in 2024 to USD 13.01 billion by 2037, exhibiting a CAGR of more than 13.6% during the forecast timeline, between 2025 and 2037.
North America industry is estimated to hold largest revenue share of 32% by 2037, owing to increasing adoption of new technologies for the treatment of cancer cases in the region.
The major players in the market include Amgen Inc., Novartis AG Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., NewLink Genetics Corp, Infinity Pharmaceuticals, Inc., and Celgene Corporation.
